Novel aromatase inhibitors by structure-guided design

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Human cytochrome P450 aromatase synthesizes estrogens from androgens.
• Aromatase inhibitors (AIs) like exemestane are key treatments for estrogen-dependent breast cancer.
• Understanding the androgen-specific active site of aromatase is crucial for drug design.

Purpose of the Study:

• To design novel C6-substituted androsta-1,4-diene-3,17-dione aromatase inhibitors.
• To evaluate the inhibitory potency and antiproliferative effects of these novel compounds.
• To elucidate the structure-activity relationships through X-ray crystallography.

Main Methods:

• Structure-guided design of novel C6-substituted androsta-1,4-diene-3,17-dione derivatives.
• Inhibition assays using purified placental aromatase to determine IC(50) values.
• Antiproliferation studies in MCF-7 breast cancer cell line to determine EC(50) values.
• X-ray crystallography to determine the binding mode of potent inhibitors.

Main Results:

• Several novel C6-substituted 2-alkynyloxy compounds exhibited nanomolar IC(50) values against purified aromatase.
• Some compounds demonstrated EC(50) values below 1 nM in MCF-7 cells, outperforming exemestane.
• X-ray structures revealed novel side groups occupying previously unoccupied channel regions, confirming the design strategy.

Conclusions:

• Structure-guided design is effective for developing potent next-generation aromatase inhibitors.
• Novel C6-substituted compounds show significant promise for treating estrogen-dependent breast cancer.
• The findings validate the use of aromatase-specific interactions in designing targeted cancer therapies.